We would like to take this opportunity to welcome Brian Andresen to the C Diff Foundation as Chairperson of Biologic Research and Development Committee.
Brian Andresen has a twenty-year record of biopharmaceutical success working with products that prevent and/or treat infectious diseases for companies such as Bayer, Wyeth Pharmaceuticals, Pfizer and Synthetic Biologics.
While at Wyeth, Brian collaborated with leading healthcare professionals, including Infectious Diseases specialists, to relate how antimicrobial use influences emerging bacterial resistance. This inspired Brian to devote himself to communicating these risks with the healthcare community, and to explore strategies to mitigate the consequences of antibiotic use such as the risk of emerging bacterial resistance and Clostridium Difficile Infection (CDI).
Brian joined Synthetic Biologics in 2013 as a marketing consultant. Synthetic Biologics is developing oral beta-lactamase enzymes that target the prevention of CDI associated with the administration of certain beta-lactam antibiotics.
Brian Andresen, Chairperson of Biologic Research and Development Committee (*) *Michael Kaleko, MD, PhD, Senior Vice President, Reseaerch & Development Synthetic Biologics *Joseph Sliman, MD, MPH, Senior Vice President, Clinical & Regulatory Affairs, Synthetic Biolgics *Andy Bristol, PhD, Vice President, Research & Development, Synthetic Biologics *Lewis Barrett, Senior Vice President, Commercial Strategy, Synthetic Biologics